COLOCORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COLOCORT (COLOCORT).
Colocort (hydrocortisone acetate) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as prostaglandins and leukotrienes, and suppression of immune responses.
| Metabolism | Primarily hepatic via CYP3A4; also metabolized locally in the colon. |
| Excretion | Renal: ~30% as metabolites; fecal/biliary: ~20% as metabolites; remainder metabolized with minimal unchanged drug excreted. |
| Half-life | Terminal elimination half-life: 2.5–3.5 hours (mean ~3 hours). No active metabolites, so duration of action correlates with half-life. |
| Protein binding | ~85% bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | 1.4–2.3 L/kg (approx 100–160 L in 70 kg adult). Indicates extensive tissue distribution. |
| Bioavailability | Oral: ~20–25% (first-pass metabolism); Rectal enema: ~15–20% (avoidance of first-pass but incomplete absorption); Rectal foam: ~10–15% (limited retention). |
| Onset of Action | Oral: 3–5 hours; Rectal enema: 1–3 hours; Rectal foam: 2–4 hours. Clinical effect onset delayed due to time required for mucosal healing. |
| Duration of Action | Oral: 12–24 hours (single dose); Rectal enema/foam: 12–24 hours; Duration limited by half-life but once-daily dosing effective due to local effects. |
10 mg rectally administered once daily, preferably at bedtime, as a retention enema.
| Dosage form | ENEMA |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment due to potential for increased systemic exposure. |
| Pediatric use | Safety and efficacy not established in pediatric patients below 18 years. |
| Geriatric use | No specific dose adjustment; use with caution due to potential for increased sensitivity and adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COLOCORT (COLOCORT).
| Breastfeeding | Budesonide is excreted into breast milk in low amounts. The milk-to-plasma ratio is approximately 0.13. At maternal oral doses up to 9 mg/day, the estimated infant daily dose is less than 1% of the maternal weight-adjusted dose. Inhaled budesonide results in even lower exposure. Considered compatible with breastfeeding, but observe infant for growth and adrenal function. |
| Teratogenic Risk | COLOCORT (budesonide) is a corticosteroid. In pregnancy, oral budesonide is not associated with a significant increase in major congenital malformations based on population-based cohort studies. First trimester exposure does not show increased risk of orofacial clefts. Second and third trimester exposure may be associated with reduced fetal growth and increased risk of neonatal adrenal suppression if used chronically at high doses. No documented fetal risk in inhaled form at recommended doses. |
■ FDA Black Box Warning
There is no FDA black box warning for Colocort.
| Serious Effects |
["Hypersensitivity to hydrocortisone or any component","Systemic fungal infections","Obstruction, abscess, or perforation of the bowel","Recent intestinal surgery"]
| Precautions | ["Local irritation or burning sensation","Systemic absorption may cause adrenal suppression, especially with prolonged use or large doses","Increased risk of infection","Masking of infection symptoms","Perforation risk in severe inflammatory bowel disease","Use with caution in patients with diverticulitis, fistulas, or intestinal anastomoses"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. For prolonged use, assess fetal growth via ultrasound every 4-6 weeks. Neonates exposed to high doses in third trimester should be monitored for adrenal suppression (e.g., hypoglycemia, hypotension). |
| Fertility Effects | No evidence of impaired fertility in humans. In animal studies, high doses caused reduced fertility. In patients with inflammatory bowel disease, improved disease control may enhance fertility. No known direct adverse effect on spermatogenesis or ovulatory function. |